Genmab, Seattle Genetics deal

Seattle Genetics granted Genmab rights to use its antibody-drug conjugate (ADC) technology with Genmab's preclinical cancer candidate HuMax-TF-ADC, an ADC against tissue factor. Genmab is responsibl...